The medicine is tested in Japan
Japanese company Sumitomo Dainippon Pharma and British company Exscientia announced the start of the first phase of a clinical trial of the drug DSP-1181, created using artificial intelligence. According to the source, this is the first case of human testing of a drug created by AI.
More specifically, the drug DSP-1181 was created jointly by the specialists of Sumitomo Dainippon Pharma and Exscientia using the Centaur Chemist AI platform, designed to search for drugs. Project participants note that the use of AI allowed to complete the stage of exploratory research in less than 12 months, while the average indicator using traditional research methods is 4.5 years.
The drug is being tested in Japan as a treatment for obsessive-compulsive disorder (OCD). OCD is a mental disorder characterized by the presence of obsessive thoughts, memories, movements and actions, as well as a variety of pathological fears. The mechanism of OCD has not yet been clarified, but according to the latest ideas, the disorder is associated with impaired communication between certain areas of the brain due to a lack of serotonin. The number of patients suffering from OCD in Japan exceeds 1 million, while in the United States it is estimated at about 3 million.